{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:02:35Z","timestamp":1794733355000,"version":"4.9.1"},"reference-count":129,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold><jats:italic>Purpose:<\/jats:italic>To assess which antiepileptic medications (AEDs) have the best evidence for long\u2010term efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or untreated epilepsy.<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic>A 10\u2010member subcommission of the Commission on Therapeutic Strategies of The International League Against Epilepsy (ILAE), including adult and pediatric epileptologists, clinical pharmacologists, clinical trialists, and a statistician evaluated available evidence found through a structured literature review including MEDLINE,<jats:italic>Current Contents<\/jats:italic>and the<jats:italic>Cochrane Library<\/jats:italic>for all applicable articles from 1940 until July 2005. Articles dealing with different seizure types (for different age groups) and two epilepsy syndromes were assessed for quality of evidence (four classes) based on predefined criteria. Criteria for class I classification were a double\u2010blind randomized controlled trial (RCT) design, \u226548\u2010week treatment duration without forced exit criteria, information on \u226524\u2010week seizure freedom data (efficacy) or \u226548\u2010week retention data (effectiveness), demonstration of superiority or 80% power to detect a \u226420% relative difference in efficacy\/effectiveness versus an adequate comparator, and appropriate statistical analysis. Class II studies met all class I criteria except for having either treatment duration of 24 to 47 weeks or, for noninferiority analysis, a power to only exclude a 21\u201330% relative difference. Class III studies included other randomized double\u2010blind and open\u2010label trials, and class IV included other forms of evidence (e.g., expert opinion, case reports). Quality of clinical trial evidence was used to determine the strength of the level of recommendation.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic>A total of 50 RCTs and seven meta\u2010analyses contributed to the analysis. Only four RCTs had class I evidence, whereas two had class II evidence; the remainder were evaluated as class III evidence. Three seizure types had AEDs with level A or level B efficacy and effectiveness evidence as initial monotherapy: adults with partial\u2010onset seizures (level A, carbamazepine and phenytoin; level B, valproic acid), children with partial\u2010onset seizures (level A, oxcarbazepine; level B, None), and elderly adults with partial\u2010onset seizures (level A, gabapentin and lamotrigine; level B, None). One adult seizure type [adults with generalized\u2010onset tonic\u2013clonic (GTC) seizures], two pediatric seizure types (GTC seizures and absence seizures), and two epilepsy syndromes (benign epilepsy with centrotemporal spikes and juvenile myoclonic epilepsy) had no AEDs with level A or level B efficacy and effectiveness evidence as initial monotherapy.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic>This evidence\u2010based guideline focused on AED efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or untreated epilepsy. The absence of rigorous comprehensive adverse effects data makes it impossible to develop an evidence\u2010based guideline aimed at identifying the overall optimal recommended initial\u2010monotherapy AED. There is an especially alarming lack of well\u2010designed, properly conducted RCTs for patients with generalized seizures\/epilepsies and for children in general. The majority of relevant existing RCTs have significant methodologic problems that limit their applicability to this guideline's clinically relevant main question. Multicenter, multinational efforts are needed to design, conduct and analyze future clinically relevant RCTs that can answer the many outstanding questions identified in this guideline. The ultimate choice of an AED for any individual patient with newly diagnosed or untreated epilepsy should include consideration of the strength of the efficacy and effectiveness evidence for each AED along with other variables such as the AED safety and tolerability profile, pharmacokinetic properties, formulations, and expense. When selecting a patient's AED, physicians and patients should consider all relevant variables and not just efficacy and effectiveness.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2006.00585.x","type":"journal-article","created":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T17:13:07Z","timestamp":1153415587000},"page":"1094-1120","source":"Crossref","is-referenced-by-count":634,"title":["ILAE Treatment Guidelines: Evidence\u2010based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes"],"prefix":"10.1111","volume":"47","author":[{"given":"Tracy","family":"Glauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Ben\u2010Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Cnaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"Kalviainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbjorn","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"33","volume-title":"Clinical practice guidelines: directions for a new program","author":"Institute of Medicine"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01167.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb05199.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07750-4"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07816-9"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10531-7"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980630)17:12<1403::AID-SIM834>3.0.CO;2-Y"},{"key":"e_1_2_8_12_2","volume-title":"Version 6 with Cytel StudioTM Statistical Software for Exact Nonparametric Inference","author":"Cytel, StatXact","year":"2003"},{"key":"e_1_2_8_13_2","first-page":"107","volume-title":"Acute pain management: operative or medical procedures and trauma, in Clinical Practice Guideline No. 1","author":"U.S. Department of Health and Human Services"},{"key":"e_1_2_8_14_2","volume-title":"American Academy of Neurology Clincal Practice Guideline Process Manual","author":"Edlund W","year":"2004"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123693.82339.FC"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.06204.x"},{"issue":"5","key":"e_1_2_8_17_2","first-page":"S39","article-title":"Consensus statements: medical management of epilepsy","volume":"51","year":"1998","journal-title":"Neurology"},{"key":"e_1_2_8_18_2","first-page":"1","article-title":"Management of newly diagnosed patients with epilepsy: a systematic review of the literature","volume":"39","author":"Ross SD","year":"2001","journal-title":"Evid Rep Technol Assess (Summ)"},{"issue":"1","key":"e_1_2_8_19_2","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.33588\/rn.35S1.2002188","article-title":"(Evidence based treatment of epilepsy)","volume":"35","author":"Armijo JA","year":"2002","journal-title":"Rev Neurol"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80128-2"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.12.003"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01316.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.944"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2001.0528"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738030180041401"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1982.tb05437.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01295.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262040-00004"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00110.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.18200.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.46401.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6471.815"},{"key":"e_1_2_8_34_2","first-page":"472","article-title":"A double\u2010blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy","volume":"52","author":"Dam M","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.6.682"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.44"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00024-7"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01013-3"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1282"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb05562.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000048200.12663.BC"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00093.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00485.x"},{"key":"e_1_2_8_46_2","volume-title":"Trileptal Prescribing Information","author":"Novartis Pharmaceutical","year":"2004"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00271-6"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06152.x"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.7.904"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.45401.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.7.639"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00085-2"},{"key":"e_1_2_8_53_2","first-page":"434","article-title":"Efficacy of sodium valproate in partial epilepsy: crossed study of valproate and carbamazepine","volume":"140","author":"Loiseau P","year":"1984","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.45.1.55"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90048-C"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540340081016"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.45.12.1113"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1940.02280010078005"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91176-U"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb04330.x"},{"key":"e_1_2_8_61_2","first-page":"606","article-title":"Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy","volume":"39","author":"Rastogi P","year":"1991","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00074-5"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550100086018"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1994.tb01640.x"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01062.x"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90099-F"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1006\/ebeh.2002.0337"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.20801.x"},{"key":"e_1_2_8_69_2","first-page":"CD001911","article-title":"Carbamazepine versus phenytoin monotherapy for epilepsy","volume":"2002","author":"Tudur Smith C","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_70_2","first-page":"CD001769","article-title":"Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic\u2010clonic seizures","volume":"2001","author":"Tudur Smith C","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_71_2","first-page":"CD002217","article-title":"Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic\u2010clonic seizures","volume":"2001","author":"Taylor S","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_72_2","first-page":"CD001904","article-title":"Carbamazepine versus phenobarbitone monotherapy for epilepsy","volume":"2003","author":"Tudur Smith C","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-5050(02)00044-6"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1995.tb11978.x"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90074-4"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00025-9"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01444.x"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06250-8"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738040190020901"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.5.605"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb05773.x"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307388600100408"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb03623.x"},{"key":"e_1_2_8_84_2","volume-title":"Advances in drug monitoring","author":"Nolte RW","year":"1980"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00516.x"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1991.tb14917.x"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1993.tb11616.x"},{"key":"e_1_2_8_88_2","unstructured":"GlauserTA DlugosDJ DodsonWE et al.A double\u2010blind dose\u2010controlled study evaluated topiramate as monotherapy in 470 patients with newly diagnosed (\u22643 months) epilepsy or epilepsy relapse in the absence of therapy. (in press.)"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000167384.68207.3E"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(99)00039-X"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02448.x"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6974(05)80021-0"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01268.x"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1487"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb05118.x"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(99)00113-8"},{"key":"e_1_2_8_97_2","first-page":"549","article-title":"Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double\u2010blind study","volume":"33","author":"Thilothammal N","year":"1996","journal-title":"Indian Pediatr"},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389601100611"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00805.x"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1982.tb13703.x"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.2.157"},{"key":"e_1_2_8_102_2","first-page":"301","volume-title":"Advances in epileptology","author":"Martinovic Z"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.40903.x"},{"key":"e_1_2_8_104_2","first-page":"CD003032","article-title":"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents","volume":"2003","author":"Posner EB","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_105_2","first-page":"47","volume-title":"Royal Society of Medicine International Congress and Symposium, No. 30: the place of sodium valproate in the treatment of epilepsy","author":"Callaghan N"},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04606.x"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(97)00575-5"},{"issue":"6","key":"e_1_2_8_108_2","first-page":"163","article-title":"Gabapentin (Neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36\u2010week, double\u2010blind, placebo\u2010controlled study","volume":"39","author":"Bourgeois B","year":"1998","journal-title":"Epilepsia"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(03)00003-2"},{"key":"e_1_2_8_110_2","first-page":"1067","article-title":"(Monotherapy with clobazam in epilepsies in children)","volume":"12","author":"Dulac O","year":"1983","journal-title":"Presse Med"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(00)00162-4"},{"key":"e_1_2_8_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00004-9"},{"key":"e_1_2_8_113_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199804000-00004"},{"key":"e_1_2_8_114_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199902000-00014"},{"key":"e_1_2_8_115_2","first-page":"160","article-title":"A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy: pilot study results in 20th IEC","volume":"34","author":"Timmings PR","year":"1993","journal-title":"Epilepsia"},{"key":"e_1_2_8_116_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05479.x"},{"key":"e_1_2_8_117_2","first-page":"39","article-title":"Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy","volume":"41","author":"Smith KB","year":"2000","journal-title":"Epilepsia"},{"key":"e_1_2_8_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(96)80110-5"},{"key":"e_1_2_8_119_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.10.1424-a"},{"issue":"6","key":"e_1_2_8_120_2","first-page":"S139","article-title":"Topiramate in patients with juvenile myoclonic epilepsy","volume":"39","author":"Rosenfeld W","year":"1998","journal-title":"Epilepsia"},{"issue":"7","key":"e_1_2_8_121_2","first-page":"184","article-title":"Effectiveness of open\u2010label zonisamide in juvenile myoclonic epilepsy","volume":"42","author":"Mullin PSJM","year":"2001","journal-title":"Epilepsia"},{"key":"e_1_2_8_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(98)90010-3"},{"key":"e_1_2_8_123_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb05769.x"},{"key":"e_1_2_8_124_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.3.285"},{"key":"e_1_2_8_125_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0432"},{"key":"e_1_2_8_126_2","first-page":"525","article-title":"Ruckfall: Prognose nach reduction der medikamente bei epilepsiebehandling","volume":"54","author":"Janz D","year":"1983","journal-title":"Nervenarzt"},{"key":"e_1_2_8_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(98)90005-X"},{"key":"e_1_2_8_128_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05833.x"},{"key":"e_1_2_8_129_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1995.tb138476.x"},{"key":"e_1_2_8_130_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1757"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2006.00585.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2006.00585.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:36:55Z","timestamp":1736469415000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2006.00585.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1528-1167.2006.00585.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00585.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}